ImmunoGen, Inc. (0A8K.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 04:33PM BST
| Previous close | 3.7585 |
| Open | 3.8800 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.8800 - 3.8800 |
| 52-week range | 3.8800 - 3.8800 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5890 |
| Earnings date | 04 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
ImmunoGen (IMGN) Down 16.6% Since Last Earnings Report: Can It Rebound?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
ImmunoGen (NASDAQ:IMGN) investors are sitting on a loss of 66% if they invested five years ago
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
- Business Wire
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
WALTHAM, Mass., March 25, 2023--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturda
© 2023 Yahoo. All rights reserved.
